News | June 08, 2010

Molecular Agent Coupled With Processing Improves Heart Imaging

June 8, 2010 – A recent study found a potential new molecular imaging agent combined with post-scan image processing technology could result in crisper pictures of the heart. The results were revealed yesterday at the Society of Nuclear Medicine (SNM) annual meeting in Salt Lake City.

“Both cardiac and respiratory motion degrade image quality by adding some unwanted blur,” said Ludovic Le Meunier, Ph.D., lead researcher and staff scientist for Siemens Healthcare, based at Cedars-Sinai Medical Center, Los Angeles, Calif. “Our objective in this work was to provide the highest myocardial perfusion image quality by using a promising heart imaging agent and correcting the motion of those organs. In conjunction, these tools can provide unprecedented diagnostic capability for clinicians evaluating heart disease.”

The New Agent

The new imaging agent, called flurpiridaz F-18 injection, uses a fluorine-18 (F-18) based radioisotope, and while it is still in clinical trials the compound has been shown to facilitate very high quality imaging of the heart. Other positron emission tomography (PET) agents used to image the heart have a much shorter half-life and need to be produced within an on-site cyclotron, which limits access. Some agents can be produced on site with a generator, but image quality appears not to be as high. F-18 has a half-life of 108 minutes and therefore can be delivered to imaging centers located within a wider radius, with no compromise to image quality.

The technology used in this study included high-definition (HD) PET, a technique that images the body’s physiological functions and automatically corrects distortions that occur during scanning. Next, researchers used post-scan image processing tools called respiratory gating and “motion frozen” cardiac gating, which cut out or otherwise compensate for the motion of these organs during scanning. The result is virtually motion-free myocardial perfusion imaging.

This clinical trial was led by Daniel Berman, M.D., director of cardiac imaging and nuclear cardiology at Cedars-Sinai Medical Center. Motion-frozen technology was developed in collaboration with Piotr Slomka, Ph.D., a research scientist at Cedars-Sinai and professor of medicine at the University of California, Los Angeles.

Trial Details

The preliminary data was from a single site participating in the multicenter phase two clinical trial for flurpiridaz F-18 injection (formerly known as BMS747158). The study so far shows the agent provides better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the noninvasive detection of coronary artery disease (CAD). The data also indicated that PET imaging with flurpiridaz F-18 injection rendered a significantly larger perfusion defect size when compared with the corresponding defects seen in SPECT imaging.

“These encouraging preliminary data from our clinical research site show that PET imaging with flurpiridaz F-18 injection provided improved images," Berman said. "A PET imaging agent that may provide higher quality images with more obvious perfusion defects can have a profound effect on physicians’ ability to make more definitive assessments of coronary artery disease.”

Twenty-six patients in a single study center underwent SPECT and PET imaging within six months. PET myocardial perfusion imaging was performed with flurpiridaz F-18 injection at rest and was then followed one hour later with imaging at exercise or under pharmacologically-induced (adenosine) stress.

For more information: www.siemens.com/healthcare, www.lantheus.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init